Johnson & Johnson (JNJ) stock
JNJ · Johnson & Johnson · NYSE
What is the latest news on JNJ stock?
JNJ rose 1.35% to $270.83 on Nov 20, 2026. No JNJ story in the last two days; the most recent is below.
TREMFYA showed statistically significant improvement in disease activity on the BASDAI score versus placebo, reflecting meaningful reductions in pain, stiffness, swelling and fatigue in a Phase 4 studyTREMFYA demonstrated more than 2 times greater reduction in MRI-assessed inflammation versus placebo at Week 24 in the sacroiliac joints, which connect the lower spine to the pelvis and are responsible for pain and stiffnessTREMFYA was evaluated in first-ever PsA study using objective MRI assessments to confirm and measure axial inflammation alongside patient-reported symptoms NEW BRUNSWICK, N.J., Nov. 20, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced late-breaking results f
All JNJ newsWhen does Johnson & Johnson report earnings?
The latest Johnson & Johnson earnings release came out on Oct 13, 2026: Johnson & Johnson reports Q3 2026 results, raises 2026 guidance. Before that, Johnson & Johnson reported on Jul 22, 2026 and Apr 14, 2026. On that schedule the next report would come around mid January 2027.
JNJ earnings historyWho owns the most JNJ stock?
BlackRock, Inc. was the largest reported holder of JNJ at the end of Q2 2026, with 212,098,264 shares worth $53.9 billion. Next came Vanguard Capital Management LLC ($39.9 billion) and State Street Corp ($34.0 billion). In all, 4,673 institutions reported $457.4 billion of JNJ in their 13F filings.
All JNJ fund holdersAre insiders buying or selling JNJ?
Insiders are selling. In the last 90 days 2 insiders sold $12.9 million of JNJ in trades reported on Form 4. The latest: Elizabeth Forminard sold $3.7 million, reported on Nov 13, 2026.
JNJ insider tradesFinancial highlights
Full financials- Revenue, TTM
- $99.33B
- Revenue growth
- +7.8%
- Net income, TTM
- $16.09B
- Net margin
- 16.2%
- Free cash flow, TTM
- $20.59B
- Cash
- $16.91B
For the twelve months ended Sep 27, 2026, from SEC filings. Not investment advice.
Latest news
25 items- PRJohnson & Johnson data in psoriatic arthritis (PsA) shows TREMFYA (guselkumab) is the only advanced therapy to demonstrate MRI-confirmed improvements in spinal pain and stiffnessTREMFYA showed statistically significant improvement in disease activity on the BASDAI score versus placebo, reflecting meaningful reductions in pain, stiffness, swelling and fatigue in a Phase 4 studyTREMFYA demonstrated more than 2 times greater reduction in MRI-assessed inflammation versus placebo at Week 24 in the sacroiliac joints, which connect the lower spine to the pelvis and are responsible for pain and stiffnessTREMFYA was evaluated in first-ever PsA study using objective MRI assessments to confirm and measure axial inflammation alongside patient-reported symptoms NEW BRUNSWICK, N.J., Nov. 20, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced late-breaking results f
- PRJohnson & Johnson Announces First Commercial Installation of the OTTAVA™ Robotic Surgical System at Memorial Hermann Health SystemCommercial agreement marks the next milestone in bringing a new category of soft-tissue robotics to hospitals and patients across the United States Installation at Memorial Hermann-Texas Medical Center builds on years of clinical collaboration, including recent clinical evaluation of the OTTAVA™ Robotic Surgical System in Roux-en-Y Gastric Bypass OTTAVA™ received U.S. FDA Authorization in July for use in ten general surgery procedures within the upper abdomen Johnson & Johnson today announced that Memorial Hermann-Texas Medical Center in Houston, Texas will be the first hospital to install the OTTAVA™ Robotic Surgical System, representing a major milestone in the commercial launch of
- PRJohnson & Johnson Seeks U.S. FDA Approval for CAPLYTA in Bipolar Mania, Marking Fifth Potential IndicationTwo positive Phase 3 studies showed CAPLYTA significantly reduced manic symptoms versus placebo as early as Day 3, with improvement sustained through Week 3As the first and only FDA-approved treatment for both bipolar I and II depression in adults as a monotherapy and adjunctive therapy, filing seeks to expand CAPLYTA for the treatment of manic or mixed episodes associated with bipolar I disorderApproval would mark the fifth approved use of CAPLYTA in adults, building on its robust efficacy and established safety and tolerability profile across major depressive disorder, bipolar depression and schizophreniaNEW BRUNSWICK, N.J., Nov. 19, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today
- PRJohnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmologyAcquisition adds OLN324, a Phase 3 investigational bispecific antibody for retinal vascular diseases, including wet AMD and diabetic macular edema Accelerates Company’s ambition to preserve, restore and enhance vision Builds on Johnson & Johnson’s long-standing presence as an innovator in vision Johnson & Johnson (NYSE:JNJ) today announced it has entered into a definitive agreement to acquire Ollin Biosciences, Inc., ("Ollin") a clinical-stage biopharmaceutical company developing therapies for serious eye diseases, for $2.2 billion upfront, with the potential for additional regulatory and commercial milestone payments. Johnson & Johnson will also enter into a separate development
- INSIDEREVP, Chief Legal Officer Forminard Elizabeth exercised 13,072 shares at a strike of $151.41 and sold $3,717,546 worth of shares (13,072 units at $284.39) (SEC Form 4)4 - JOHNSON & JOHNSON (0000200406) (Issuer)
- FDAFDA Approval for LAZCLUZE issued to JANSSEN BIOTECHSubmission status for JANSSEN BIOTECH's drug LAZCLUZE (SUPPL-5) with active ingredient LAZERTINIB MESYLATE has changed to 'Approval' on 11/12/2026. Application Category: NDA, Application Number: 219008, Application Classification: Labeling
- PRJohnson & Johnson Announces CAPLYTA (lumateperone) Shows Significant and Rapid Improvement in Bipolar Mania in Second Pivotal Phase 3 StudyCAPLYTA improved manic symptoms versus placebo as early as Day 3, with improvement sustained through Week 3 and a safety and tolerability profile consistent with prior studiesTwo positive Phase 3 studies will support a planned U.S. FDA submission of CAPLYTA for bipolar mania, reinforcing its potential to address both depressive and manic episodes of bipolar disorderNEW BRUNSWICK, N.J., Nov. 10, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced that Study 452, the second pivotal Phase 3 study evaluating CAPLYTA (lumateperone) for the treatment of manic episodes with or without mixed features in adults with bipolar I disorder, met its primary and key secondary endpoints. CAPLYT
- PRRaised Outlooks and a Cancer Approval Arrive in the Middle of Medicare Open EnrollmentNEW YORK, Nov. 9, 2026 /CNW/ -- Market Updates News Commentary - Health care stocks moved higher with the broader market on Monday morning. As of 9:58 a.m. ET, the State Street Health Care Select Sector SPDR ETF was up 0.88% at $186.42, while the S&P 500 was up 1.70% at 7,501.96. Medicare Open Enrollment is underway, and over the past week companies in pharmaceuticals, biotechnology, health insurance, medical devices and drug distribution have reported quarterly results or regulatory news. Active Companies from around the markets with current developments this week include: Johnson & Johnson (NYSE:JNJ), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Humana Inc. (NYSE:HUM), Edwards Lifesc
- PRJohnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptideLate-breaking data from Phase 3 investigational study presented at the American College of Rheumatology Convergence show 58% of ICOTYDE-treated patients achieved an ACR20 response and 29% achieved an ACR50 response at Week 16 ICOTYDE is a first-in-class IL-23R targeted oral peptide, demonstrating significant joint and skin improvements and a favorable safety profile in a once-daily pill NEW BRUNSWICK, N.J., Nov. 7, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced positive results from a Phase 3 study investigating ICOTYDE® (icotrokinra) in biologic-naïve adults with active psoriatic arthritis (PsA).a,b ICOTYDE is the first and only targeted oral peptide that precisely blocks
- PRJohnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patientsNew patient experience dataa to be presented at ACR 2026 show mouth dryness was reported as the most important symptom to improve, followed by eye dryness, fatigue and joint painPatient insights complement Phase 2 study results demonstrating a 50% increase in saliva productionb in more than twice as many patients on nipocalimab compared to placeboc Two Phase 3 studies are ongoing, evaluating nipocalimab in Sjögren's disease including these measures critical to patientsNEW BRUNSWICK, N.J., Nov. 7, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new patient experience findingsa from the Phase 2 DAHLIAS study of nipocalimab in Sjögren's disease (SjD), a chronic, systemic autoa
- FDAFDA Approval for RYBREVANT FASPRO issued to JANSSEN BIOTECHSubmission status for JANSSEN BIOTECH's drug RYBREVANT FASPRO (SUPPL-2) with active ingredient AMIVANTAMAB AND HYALURONIDASE-LPUJ has changed to 'Approval' on 11/05/2026. Application Category: BLA, Application Number: 761433, Application Classification:
- PRJohnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck CancerAccelerated approval based on data demonstrating clinically meaningful efficacy, including a 42 percent overall response rate (95 percent confidence interval, 32–52 percent)1First advancement in the second-line treatment setting for recurrent or metastatic head and neck cancer in a decade, bringing a new subcutaneous option to patients with significant unmet need2-3 Extending its well-established, dual-targeted benefit beyond lung cancer, RYBREVANT FASPRO™ targets both EGFR and MET pathways – two key drivers of tumor progression in head and neck cancer2NEW BRUNSWICK, N.J., Nov. 5, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced that the U.S. Food and Drug Administration (FD
- PRData Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI, in Contrast to CHIP-BCIS3 Study ResultsAnalyses presented at TCT highlight how patient selection, timely Impella support and consistent care protocols may help improve outcomes during and after complex heart procedures Johnson & Johnson announced results from three clinical analyses being presented during the Transcatheter Cardiovascular Therapeutics annual scientific symposium (TCT 2026) that report positive survival and patient outcomes data when Impella™ heart pumps are used to support a patient’s heart during and after high-risk percutaneous coronary intervention (HRPCI). Real-world and observational registry data from 1,379 HRPCI patients across hospitals in the U.S. and Europe show lower in-hospital cardiovascular mortal
- PRJohnson & Johnson to Host Enterprise Business ReviewJohnson & Johnson (NYSE:JNJ) will hold an Enterprise Business Review for the investment community on Tuesday, December 8th, 2026. During the event, Company leaders will provide a detailed review of the Innovative Medicine and MedTech businesses, highlight how their pipelines are shaping the future of healthcare, and discuss the Company’s long-term strategy for delivering the next wave of growth and shareholder value. The Enterprise Business Review will include a live General Session starting at 8:30 a.m. ET, followed by in-depth focus rotations, with the event concluding at approximately 3:45 p.m. ET. The program will feature: Enterprise overview from Joaquin Duato, Chairman and Chief
- SECSEC Form 13F-HR filed by Johnson & Johnson13F-HR - JOHNSON & JOHNSON (0000200406) (Filer)
- PRRYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancerResponses were deep and durable, with 65% ongoing at clinical cutoffResults support continued evaluation of the investigational RYBREVANT FASPRO regimen in the ongoing first-line Phase 3 studyData highlight the role of dual-targeting EGFR and MET, key drivers of tumor growth and resistance seen in 80 to 90 percent of HNSCC NEW BRUNSWICK, N.J., Oct. 25, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new results from Cohort 5 of the Phase 1b/2 OrigAMI-4 study showing deep and durable responses with first-line subcutaneous amivantamab and hyaluronidase-lpuj plus a PD-1 inhibitor and fixed-duration carboplatin chemotherapy in patients with recurrent or metastatic head and neck
- PRJohnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ moleculeJNJ-6143 is an investigational, once-daily, novel, small molecule designed to trigger cancer cell death through a targeted dual-protein lock between BRD4 and androgen receptor, a highly expressed tumor-selective protein in prostate cancer cellsAmong patients with measurable disease in the 50 mg cohort, 75% achieved a complete or partial tumor response in the Phase 1 study77% of patients achieved a confirmed PSA reduction of at least 50%, including nearly half whose PSA levels fell by at least 90%NEW BRUNSWICK, N.J., Oct. 25, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced promising Phase 1 results for JNJ-6143 (formerly HLD-0915), an investigational once-daily oral Regulate
- PRJohnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancerNew substudy results showed a 51% lower estimated risk of metastasis or death over time with perioperative apalutamide plus ADT compared with immediate surgeryTwice as many patients remained free from subsequent treatment at three years with perioperative apalutamide plus ADT compared with surgery aloneResults evaluated outcomes versus surgery alone, building on the primary results presented at ASCO 2026 NEW BRUNSWICK, N.J., Oct. 24, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new results from the Phase 3 PROTEUS substudy that directly compared the investigational use of apalutamide plus androgen deprivation therapy (ADT), given for six months before and after surgery,
- PRJohnson & Johnson Reports First Real-World VARIPULSE Pro Platform Data and 12-Month OMNYPULSE Platform Outcomes for Atrial Fibrillation Treatment at APHRS 2026VARIPURE findings reported 100% acute procedural success with the VARIPULSE Pro Platform, 0.4% primary adverse event rate and a mean ablation time of 17.9 minutesi Omny-IRE data showed 82.5% of patients treated with the investigational OMNYPULSE Platform1 remained free from documented atrial arrhythmia recurrence at 12 months under stringent monitoringii Johnson & Johnson (NYSE:JNJ) today announced new data from the late-breaking VARIPURE and Omny-IRE studies presented at the Asia Pacific Heart Rhythm Society (APHRS) 2026 Annual Meeting in Busan, South Korea. Both studies were published simultaneously in Europace and Heart Rhythm, respectively. This press release features multimedia. V
- SECSEC Form 10-Q filed by Johnson & Johnson10-Q - JOHNSON & JOHNSON (0000200406) (Filer)
- ANALYSTJohnson & Johnson downgraded by Erste GroupErste Group downgraded Johnson & Johnson from Buy to Hold
- PRJohnson & Johnson announces new data showing TREMFYA® (guselkumab) is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn's disease with perianal fistulaTREMFYA maintained combined fistula remission through Week 48 across both maintenance dose regimens, including an increase from 28% at Week 24 to 35% at Week 48 in the 100 mg dose groupThese findings build on the Phase 3 clinical program, demonstrating efficacy in a dedicated, randomized, placebo-controlled trial in patients with this debilitating and challenging manifestation of Crohn's disease SPRING HOUSE, Pa., Oct. 19, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced one-year results from the Phase 3 FUZION study showing TREMFYA® (guselkumab) maintained or improved fistula remission through 48 weeks in adults with Crohn's disease (CD).1 The findings build on the previous
- SECSEC Form 8-K filed by Johnson & Johnson8-K - JOHNSON & JOHNSON (0000200406) (Filer)
- PRJohnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2026 of $1.34 per share on the company’s common stock. The dividend is payable on December 8, 2026 to shareholders of record at the close of business on November 24, 2026. The ex-dividend date is November 24, 2026. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquel
- PRJohnson & Johnson reports Q3 2026 results, raises 2026 guidance2026 Third-Quarter reported sales growth of 5.9% to $25.4 Billion with operational growth of 6.0%* and adjusted operational growth of 6.1%* 2026 Third-Quarter earnings per share (EPS) of $0.09 reflects a one-time special charge for the proposed talc litigation resolution, the acquisition of Firefly Bio, Inc., and the strategic collaboration with Sail Biomedicines; adjusted EPS* of $2.59 also reflects the impact of these M&A deals Strong operational performance results in the Company increasing 2026 guidance with estimated reported sales of $101.2 Billion or 7.4% at the midpoint and increasing adjusted EPS* guidance by $0.06 to $11.10 or 2.9% at the midpoint Significant innovation
Hiring
Nov 20, 2026Johnson & Johnson lists 1,817 open roles on its careers site as of Nov 20, 2026, the most in MedTech Sales (403).
- Open roles
- 1,817
By team
- MedTech Sales403
- Pharmaceutical Sales196
- Finance98
- Medical Affairs Group93
- Supply Chain Engineering93
- Career Programs75
By location
- Chiyoda, Tokyo, Japan112
- Raritan, New Jersey, United States of America98
- Raynham, Massachusetts, United States of America78
- Shanghai, China70
- Titusville, New Jersey, United States of America58
- Spring House, Pennsylvania, United States of America53
Counted daily from Johnson & Johnson's careers site.
JNJ rankings
- Other36(71%)
- Insider6(12%)
- Earnings3(6%)
- Analyst2(4%)
- SEC Filings2(4%)
- M&A2(4%)
Our reporting on JNJ
- J&J agrees to buy eye-disease biotech Ollin, a $3.4 billion entry into retina drugsAnalysis · Nov 16, 2026 · 7 min read

- FDA approves AstraZeneca's KLYGEFA for myasthenia gravis, a weekly self-injected C5 drugAnalysis · Nov 13, 2026 · 6 min read

- FDA Grants Rybrevant Faspro Accelerated Approval in Head and Neck Cancer on a 42% Response Rate, but the Confirmatory Trial Tests a Different LineAnalysis · Nov 6, 2026 · 6 min read

- Gilead's PURPOSE 5: 85.6% of lenacapavir users stay on PrEP at one year vs 46.3% on daily pillsAnalysis · Nov 6, 2026 · 6 min read

Johnson & Johnson (JNJ) is a Biotechnology: Pharmaceutical Preparations company listed on NYSE. In the last 30 days Quantisnow tracked 18 wire items for JNJ, including 15 press releases and news items, 2 M&A updates and 1 insider trade. The most recent was published Nov 20, 2026.
JNJ FAQ
10 questionsWhat does Johnson & Johnson do?
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL...What is JNJ revenue?
Johnson & Johnson (JNJ) reported $99.33B of revenue for the twelve months ended Sep 27, 2026. That is up 7.8% from the year before. Revenue for fiscal 2025 was $94.19B.Is JNJ profitable?
Yes. Johnson & Johnson earned $16.09B in net income for the twelve months ended Sep 27, 2026, a net margin of 16.2%.How much cash and debt does JNJ have?
Johnson & Johnson reported $16.91B in cash and cash equivalents and $44.65B of debt on its most recent balance sheet in SEC filings.Is Johnson & Johnson (JNJ) hiring?
Johnson & Johnson lists 1,817 open roles on its careers site as of Nov 20, 2026, the most in MedTech Sales (403). The most openings are in Chiyoda, Tokyo, Japan, Raritan, New Jersey, United States of America and Raynham, Massachusetts, United States of America.Where does JNJ stock trade?
Johnson & Johnson (JNJ) is listed on NYSE.What sector and industry is JNJ in?
Johnson & Johnson operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about JNJ?
Across the last 8 analyst actions on Johnson & Johnson, there were 4 upgrades and 1 downgrade. The most recent action was from Erste Group: Hold on 2026-10-21. Recent price targets range from $203.00 to $320.00.What companies are similar to JNJ?
Notable peers in the same industry include MRK (Merck & Company Inc.), ABT (Abbott Laboratories), PFE (Pfizer Inc.), MDT (Medtronic plc.), SYK (Stryker Corporation). Compare JNJ side-by-side with any of them on Quantisnow.How can I track JNJ on Quantisnow?
Quantisnow aggregates Johnson & Johnson's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow JNJ to receive live email and push alerts on every new disclosure.
Is something on this page wrong, or out of date? Request a change